

PURPOSE/INTRODUCTION

- ▶ Ocular Tuberculosis occurs through hematogenous dissemination of Mycobacterium tuberculosis from a primary site of infection (usually pulmonary)
- ▶ Tuberculosis Uveitis prevalence is variable, being higher in developing countries.

METHODS

- ▶ This case report was obtained by literary review of scientific articles and evaluation of the patient's medical record

RESULTS

- ▶ 46 yo female presents low vision complaint for the last 6 months on OD.
- ▶ PFH relates her Father treated Pulmonary TB 5 Years ago.
- ▶ Ophthalmologic examination:
 - ▶ BCVA 20/100 OD, 20/20 OS | IOP = 17mmHg OU
 - ▶ BMA diffuse scarce KP's on the cornea OD. ACR +2/4 OD. OS was normal
 - ▶ Fundus: (Images)
 - ▶ OD Large exudative White-yellowish lesion from peripapillary region to nasal periphery and Nasal Superior CR lesion. OS was normal;
 - ▶ Lab: A Mantoux test was performed (PPD) = 25mm
- ▶ Her initial empiric treatment for Ocular Toxoplasmosis was suspended and she was then promptly forwarded to Infectology and oral RIPE was Initiated.

DISCUSSION

- ▶ Ocular Tuberculosis can manifest as Anterior, Intermediary or posterior uveitis.
- ▶ Posterior Uveitis is the most common presentation of ocular TB and can itself present as a myriad of entities:
 - ▶ Choroid Tuberculae, Multifocal Choroiditis
 - ▶ Choroid/Retinal Granulomas, Subretinal Abscesses
 - ▶ Serpiginous-like choroiditis, Retinal Vasculitis
 - ▶ Exsudative Retinal Detachment, Neuroretinitis
 - ▶ Cystoid Macular Oedema
- ▶ Implemented treatment (RIPE) led to disease activity and inflammation decrease. Images were taken on presentation and 3 months.

CONCLUSION

- ▶ The present case raises the importance of considering ocular tuberculosis as a differential diagnosis in patients with chorioretinitis, (extensive or not) - specially if it consists of a chronic active lesion - and the importance of early diagnosis and prompt treatment to prevent vision loss and potential systemic spread of the disease
- ▶ Current Treatment for ocular TB include RIPE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) Orally. The duration depends on individual circumstances and case severity, but usually a 9-month period.

